Epub – JAMA Psychiatry: Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia

June 5, 2019

Volk DW, Lewis DA

Changes in state laws that have made cannabis more available for medical indications or recreational use have raised concerns about potential unintended negative societal consequences of cannabis use. For example, epidemiologic studies have reported associations between cannabis use and schizophrenia, including a greater risk of developing the disorder, an earlier age at onset, more severe symptoms, and more frequent hospitalizations. Furthermore, a 2018 large-scale genome-wide association study reported that genetic risk for schizophrenia is also associated with a causal positive risk for cannabis use, suggesting a deleterious interaction in which individuals at risk for the disorder are more likely to start using cannabis during susceptible periods of life such as adolescence, leading to more adverse consequences. Consequently, understanding the pathophysiologic mechanism(s) by which cannabis use may affect the onset and course of schizophrenia requires an understanding of the status of the neural target of cannabis, the endogenous cannabinoid (endocannabinoid) system, in individuals with schizophrenia.

Volk DW, Lewis DA. Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia. JAMA Psychiatry. 2019 Jun 5. doi: 10.1001/jamapsychiatry.2019.0844. [Epub ahead of print] PMID: 31166594.

https://www.ncbi.nlm.nih.gov/pubmed/31166594

Translational Neuroscience Program

Understanding the Brain
to Improve Mental Health

 

 

 

 

© 2020 University of Pittsburgh

            a

Assistant Director
slovsl@upmc.edu

            a

University of Pittsburgh
3811 O'Hara Street, BST W1651
Pittsburgh, PA 15213

            a

University of Pittsburgh
Department of Psychiatry

W1651 Biomedical Science Tower
203 Lothrop Street
Pittsburgh, PA 15213

Bridgeside Point II, Suite 223
450 Technology Drive
Pittsburgh, PA 15219

a

412-624-3894